Brokerage firm Prabhudas Lilladher has initiated coverage on HealthCare Global Enterprises (HCG) with a target price of Rs 820. The report highlights the company's strong first-quarter results and a clear strategic shift toward high-growth oncology services. Investors are watching the potential benefits of the fertility business divestment and capacity expansion, while remaining aware of sector-wide regulatory price pressures.
Prabhudas Lilladher has initiated a 'BUY' rating on HealthCare Global Enterprises (HCG), setting a target price of Rs 820 per share. The brokerage report highlights that the hospital operator is benefiting from a combination of operational efficiency and a refocused business strategy. This initiation comes following a strong performance in the first quarter of the 2027 fiscal year, where the company demonstrated solid growth metrics.
Strong Financial Performance in Q1
The company’s recent financial results showed a positive trend, with revenue for the first quarter of FY27 reaching INR 6,951 million, marking a 13% increase compared to the previous year. A key highlight was the adjusted EBITDA, which rose to approximately INR 1.34 billion, representing roughly 20% year-on-year growth. The company’s operating margin also saw improvement, reaching 19.4%. These figures have formed the basis for the brokerage’s optimistic outlook, as they forecast a 24% compound annual growth rate in EBITDA between the 2026 and 2028 financial years.
Strategy Shift and Operational Efficiency
A significant factor in the current analysis is the company's decision to divest from its fertility business, known as Milann. This move is intended to allow the management team to focus exclusively on its core strength—oncology (cancer care). The company is also moving toward an asset-light model, which involves expanding its hospital bed capacity through brownfield projects rather than building entirely new hospitals from the ground up. This approach is intended to use capital more efficiently and improve returns. Additionally, the company has successfully increased its share of revenue from non-institutional sources to 69%, which often offers better payment terms than institutional contracts.
Market and Sector Risks
While the growth outlook is positive, investors should also consider the broader challenges facing the healthcare sector. One primary concern is the risk of government-imposed price caps on medical services, which can limit profit margins. There is also the execution risk associated with scaling new hospital capacity. When hospitals expand their bed count, there is typically a period where costs are incurred before the new capacity becomes fully profitable. Furthermore, the company’s current stock valuation reflects high future growth expectations. If the company fails to meet these growth targets or if margins do not expand as anticipated, it could impact the stock performance.
What Investors Should Monitor Next
The key focus for shareholders will be how effectively the company manages its new capacity expansion and whether it can sustain its current margin improvement. Market participants will be looking for updates on the utilization of new beds, especially at facilities like the North Bangalore unit, and whether the strategic shift toward oncology continues to drive higher-quality revenue. Continued improvement in the payor mix will also be an important indicator of the company’s financial health in the coming quarters.